Most interestingly, one patient who underwent ASCT for AML with mutated NPM1 and FLT3-ITD and who had no DTA-CH was diagnosed with AML with an IDH2 mutation 8.5 years later without evidence of either mutated NMP1 or FLT3-ITD or DTA mutations. The gene discussed is NPM1; the disease is acute myeloid leukemia.